Klaria Pharma Holding
Egetis attracts a bid and agrees to sell its priority review voucher, Lytix meets its endpoint in melanoma and Novo raises its outlook – the Nordic Pulse | 2026:45
Genmab clears a pivotal hurdle, AstraZeneca dominates ESMO and Bonesupport surges on Q3 – the Nordic Pulse | 2026:43– the Nordic Pulse | 2026:43
Ascendis gets the nod in Europe and Camurus wins Canada as Nordic outperformance widens – the Nordic Pulse | 2026:42
Analytics
Zealand wins in obesity, Genmab hits first-line DLBCL and Oncopeptides crosses the blood-brain barrier – the Nordic Pulse | 2026:41
A quarter of billion-euro licences, a Novo comeback and a flat Nordic index – the State of Nordic BioPharma | 2026:Q3
Analytics
